Comparative evaluation of HIV-1 neutralization in external secretions and sera of HIV-1-infected women

Open AIDS Journal

Volumn 6, Issue 1, 2012, Pages 293-302

  Wei, Qing ^a   Moldoveanu, Zina ^a   Huang, Wen Qiang ^a   Alexander, Rashada C ^a,b   Goepfert, Paul A ^c   Mestecky, Jiri ^a,d,e  

^a University of Alabama at Birmingham   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c University of Alabama at Birmingham   (United States)

^d and Clinical Center   (United States)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

HIV 1 specific antibodies; Humoral innate factors; Ig depletion; IgA; IgG; Virus neutralization

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTEIN P17; PROTEIN P31; PROTEIN P51; PROTEIN P55; PROTEIN P66; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; LAVAGE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RECTAL LAVAGE; VAGINAL LAVAGE; VIRUS INHIBITION; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

EID: 84878590621     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613601206010293     Document Type: Article

References (53)

1. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccinedesign: current approaches and future directions. Curr Opin Immunol 2010; 22: 1-9.
2. Mascola JR. Define the protective antibody response for HIV-1. Curr Mol Med 2003; 3: 209-16.
3. Mascola JR. Passive transfer studies to elucidate the role ofantibody-mediated protection against HIV-1. Vaccine 2002; 20: 1922-5.
4. Parren PW, Burton DR. The antiviral activity of antibodies in vitroand in vivo. Adv Immunol 2001; 77: 195-262.
5. Mantis NJ, Palaia J, Hessell AJ, et al. Inhibition of HIV-1infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol 2007; 179: 3411-52.
6. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titerantibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15: 951-5.
7. Hessell AJ, Pakasa EG, Tehrani DM, et al. Broadly neutralizingmonoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type I gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010; 84: 1302-13.
8. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virustransmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9: 343-6.
9. Parren PW, Marx PA, Hessell AJ, et al. Antibody protectsmacaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75: 8340-7.
10. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaquesagainst vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-10.
11. Baba TW, Liska V, Hofmann-Lehmann R, et al. Humanneutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6: 200-6.
12. Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaquesagainst pathogenic siman/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-18.
13. Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci USA 2011; 108: 4388-93.
14. Bouvet JP, Belec L, Pires R, Pillot J. Immunoglobulin G antibodiesin human vaginal secretions after parenteral vaccination. Infect Immun 1994; 62: 3957-61.
15. Berneman A, Belec L, Fischetti VA, Bouvet JP. The specificitypatterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions. Infect Immun 1998; 66: 4163-8.
16. Russell MW, Mestecky J. Humoral immune responses to microbialinfections in the genital tract. Microb Infect 2002; 4: 667-77.
17. Wright PF, Kozlowski PA, Rybczyk K, et al. Detection of mucosalantibodies in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 2002; 18: 1291-300.
18. Mestecky J, Jackson S, Moldoveanu Z, et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type-1-infected individuals. AIDS Res Hum Retroviruses 2004; 20: 972-88.
19. Alexander R, Mestecky J. Neutralizing antibodies in mucosalsecretions: IgG or IgA?. Current HIV Res 2007; 5: 588-93.
20. Mestecky J. Humoral responses to the human immunodeficiencyvirus type-1 (HIV-1) in the genital tract compared to other mucosal sites. J Reprod Immunol 2007; 73: 86-97.
21. Mestecky J, Moldoveanu Z, Smith PD, Hel Z, Alexander RC. Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol 2009; 83: 196-200.
22. Mestecky J, Wright PF, Lopalco L, et al. Scarcity or absence ofhumoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses 2011; 27: 469-86.
23. Mcneely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96: 456-64.
24. Wahl SM, McNeely TB, Janoff EN, et al. Secretory leukocyteprotease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Dis 1997; 3(Suppl 1): S64-9.
25. Kazmi SH, Naglik JR, Sweet SP, et al. Comparison of humanimmunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 2006; 13: 1111-8.
26. Harmsen MC, Swart PJ, Bethune MP, et al. Antiviral effects ofplasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995; 172: 380-8.
27. Orsi N. The antimicrobial activity of lactoferrin: current status andperspectives. Bio Metals 2004; 17: 189-96.
28. Seganti L, Biade AM, Marchetti M, Pietrantoni A, Tinari A, Superti F. Antiviral activity of lactoferrin towards naked viruses. Bio Metals 2004; 17: 295-9.
29. Lee-Huang S, Huang PL, Sun Y, et al. Lysozyme and RNase asanti-HIV components in -core preparations of human chorionic gonadotropin. Proc Natl Acad Sci USA 1999; 96: 2678-81.
30. Shine N. Concise review: the anti-HIV-1 activity associated withsaliva. J Dent Res 1997; 76: 634-40.
31. Devito C, Hinkula J, Kaul R, et al. Mucosal and plasma IgA fromHIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14: 1917-20.
32. Devito C, Hinkula J, Kaul R, et al. Cross-clade HIV-1-specificneutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 2002; 30: 413-20.
33. Fiore JR, Laddago V, Lepera A, et al. Limited secretory-IgAresponse in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. N Microbiol 2000; 23: 85-92.
34. Dorrel L, Hessell AJ, Wang M, et al. Absence of specific mucosalantibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 2000; 14: 1117-22.
35. Melissa DS, Rida W, Priddy FH, et al. Human immunodeficiencyvirus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83: 7337-48.
36. rd ed. Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, Mayer L, Eds. Collection andprocessing of human mucosal secretions. Amsterdam: Elsevier/Academic Press 2005; pp. 1829-39.
37. Russell MW, Mestecky J, Julian B, Galla J. IgA-associated renaldiseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 1986; 6: 74-86.
38. Mohamed OA, Ashley R, Goldstein A, McElrath J, Dalessio J,Corey L. Detection of rectal antibodies to HIV-1 by a sensitive chemiluminescent western blot immunodetection method. J Acquir Immune Defic Syndr 1994; 7: 375-80.
39. Moldoveanu Z, Mestecky J. Mucosal antibody responses to HIV-1.Methods Mol Biol 2009; 485: 333-45.
40. Platt, EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects ofCCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type1. J Virol 1998; 72: 2855-64.
41. Wei XP, Decker JM, Liu H, et al. Emergence of resistant humanimmunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46: 1896-905.
42. Wei, XP, Decker JM, Wang S, et al. Antibody neutralization andescape by HIV-1. Nature 2003; 422: 307-12.
43. nd ed. Measuring HIV neutralization in a luciferase reporter gene assay. New York: Humana Press 2009; pp. 395-405.
44. Edmonds TG, Ding H, Yuan X, et al. Replication competentmolecular clones of HIV-1 expressing renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010; 408: 1-13.
45. Pakkanen SH, Kantele JM, Moldoveanu Z, et al. Expression ofhoming receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids. Clin Vaccine Immunol 2010; 17: 393-401.
46. Kutteh WH, Edward RP, Menge AC, Mestecky J. In: LocalImmunity in Reproductive Tract Tissues, Griffin PD and Johnson PM, Eds. IgA immunity in female reproductive tract secretions. Delhi: Oxford University Press 1993; pp. 229-43.
47. Kutteh WH, Mestecky J. Secretory immunity in the femalereproductive tract. Am J Reprod Immunol 1994; 31: 40-6.
48. Kutteh WH, Prince SJ, Hammonds KR, Kutteh CC. Mestecky J. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin Exp Immunol 1996; 104: 538-42.
49. Kutteh WH, Moldoveanu Z, Mestecky J. Mucosal immunity in thefemale reproductive tract: correlation of immunoglobulins, cytokines and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res Hum Retroviruses 1998; 14(Suppl 1): S51-5.
50. Mestecky J, Alexander RC, Wei Q, Moldoveanu Z. Methods forevaluation of humoral immune responses in human genital tract secretions. Am J Reprod Immunol 2011; 65: 361-7.
51. Jackson S, Prince S, Kulhavy R, Mestecky J. False positivity ofenzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV type 1 antigens. AIDS Res Hum Retroviruses 2000; 16: 595-602.
52. Kozlowski PA, Jackson S. Serum IgA subclasses and molecularforms in HIV infection: selective increase in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins. AIDS Res Hum Retroviruses 1992; 8: 1773-80.
53. Brown TA, Murphy BR, Radl J, Haailman JJ, Mestecky J. Subclassdistribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J Clin Microbiol 1985; 22: 259-64.